提供的CDK4/CCND1 (人源)重组蛋白 为Abnova品牌旗下的重组蛋白产品。 产品描述 该CDK4/CCND1 (人源)重组蛋白 产品为重组表达蛋白,可广泛应用于包括SDS-PAGE或者其它功能研究,具体请查看产品说明书。 产品形式 保存建议 请在接收到CDK4/CCND1 (人源)重组蛋白 产品后按照产品操作说明书进行保存。我们建议分装以...
目的 探讨细胞周期蛋白D1(CCND1)和细胞周期蛋白依赖性激酶4(CDK4)基因多态性与早期乳腺癌发生的关系.方法 选择2018年3月至2019年3月在我院就诊的56例早期乳腺癌患者为试验组,以同期体检未发现乳腺疾病的56例健康女性为对照组.采用聚合酶链式反应(PCR)和单链构象多态性(SSCP)相结合的方法对CCND1,CDK4基因进行种...
CCND1-CDK4-mediated cell cycle progression provides a competitive advantage for human hematopoietic stem cells in vivo. T, Calegari F, Waskow C (2015) CCND1-CDK4-mediated cell cycle progression provides a competitive advantage for human hematopoietic stem cells in vivo. ... Nicole,Mende,Erika,...
Cyclin-dependent kinase 4 (CDK4); cyclin D1 (CCND1; BCL1)The crystal structure of the CDK4-CCND1 complex could help identify new CDK4 inhibitors to treat cancer.doi:10.1038/scibx.2009.264NoneScience Business Exchange
CDK4和CCND1基因 突变率分别为8.2% (11/134)、0.75%(1/134)和0%(0/134).81.8%(9/11)的P16INK4a基因突变可能影响蛋白质功能.P16INK4a野生型患者的总生存 期明显长于突变型患者(X2 = 8.872,P<0.01).P16INK4a基因突变是影响黑色素瘤的独立预后因素(P<0.05).结论 P16INK4a基因可能成为黑色素 瘤靶...
PBABE-CDK4(HUMAN)-P2A-CCND1(HUMAN)-SV40-PURO生产厂家 全球有 1家供应商PBABE-CDK4(HUMAN)-P2A-CCND1(HUMAN)-SV40-PURO国内生产厂家 供应商联系电话电子邮件国家产品数优势度 北京索莱宝科技有限公司010-50973130 17801761073Gsiyu@solarbio.com中国5074958...
increases in the number of copies of the genes for cyclin- dependent kinase 4 (CDK4) and cyclin D1 (CCND1), downstream components of the RASBRAF ... C Jafridlyand - 《N Eng J Med》 被引量: 4226发表: 2006年 Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest....
Conclusion FAT1 inhibits the proliferation and G1-to S-phase transition of ESCC cells through regulating the protein expression of CDK4/CDK6/CCND1 complex.胡晓玲翟元芳李国栋邢建峰杨洁毕炀辉王娟师如意Chinese Journal of Oncology胡晓玲,翟元芳,李国栋,等.FAT1...
This information may be instrumental for the design of novel targeted therapeutic strategies.From our data we conclude that IFITM3 is overexpressed in OSCC and may regulate the CCND1-CDK4/6-pRB axis to mediate OSCC cell growth.doi:10.1007/s13402-019-00437-z...
In silico discovery of potential PPI inhibitors for anti-lung cancer activity by targeting the CCND1-CDK4 complex via the P21 inhibition mechanismdoi:10.3389/fchem.2024.1404573Tang, WeijianShen, TaoChen, ZhoumiaoHuang, BeibeiChen, Jianzhong